Nomograms containing body dose parameters for predicting survival in patients with nasopharyngeal carcinoma-Reference-Cited by-同舟云学术

Nomograms containing body dose parameters for predicting survival in patients with nasopharyngeal carcinoma

Published:2023-08-08 Issue:1 Volume:281 Page:181-192
ISSN:0937-4477
Container-title:European Archives of Oto-Rhino-Laryngology
language:en
Short-container-title:Eur Arch Otorhinolaryngol

Author:

Jiang Jianyun,Zhai Ruiping,Kong Fangfang,Du Chengrun,Ying Hongmei^ORCID

Abstract

Abstract Purpose To assess the impact of body dose on survival outcomes in nasopharyngeal carcinoma (NPC) patients and to create novel nomograms incorporating body dose parameters for predicting survival. Methods 594 of non-metastasis NPC patients (training group, 396; validation group, 198) received intensity-modulated radiation therapy at our institution from January 2012 to December 2016. Patient characteristics, body dose parameters in dose–volume histogram (DVH) and hematology profiles were collected for predicting overall survival (OS) and progression-free survival (PFS). Nomograms for OS and PFS were developed using the selected predictors. Each nomogram was evaluated based on its C-index and calibration curve. Results Body dose-based risk score for OS (RSOS), N stage, age, and induction chemotherapy were independent predictors for OS, with a C-index of 0.784 (95% CI 0.749–0.819) in the training group and 0.763 (95% CI 0.715–0.810) in the validation group for the nomogram. As for PFS, the most important predictors were the body dose-based risk score for PFS (RSPFS), N stage, and induction chemotherapy. C-index of PFS nomogram was 0.706 (95% CI 0.681–0.720) in the training group and 0.691 (95% CI 0.662–0.711) in the validation group. The two models outperformed the TNM staging system in predicting outcomes. Conclusions Body dose coverage is a useful predictor of prognosis in clinical routine patients. The novel nomograms integrating body dose parameters can precisely predict OS and PFS in NPC patients.

Publisher

Springer Science and Business Media LLC

Subject

General Medicine,Otorhinolaryngology

Link

https://link.springer.com/content/pdf/10.1007/s00405-023-08173-9.pdf

Reference42 articles.

1. Chen Y-P, Chan ATC, Le Q-T, Blanchard P, Sun Y, Ma J (2019) Nasopharyngeal carcinoma. Lancet (London, England) 394(10192):64–80. https://doi.org/10.1016/S0140-6736(19)30956-0

2. Sun X-S, Liu S-L, Luo M-J, Li X-Y, Chen Q-Y, Guo S-S, Wen Y-F, Liu L-T, Xie H-J, Tang Q-N et al (2019) The association between the development of radiation therapy, image technology, and chemotherapy, and the survival of patients with nasopharyngeal carcinoma: a cohort study from 1990 to 2012. Int J Radiat Oncol Biol Physics 105(3):581–590. https://doi.org/10.1016/j.ijrobp.2019.06.2549

3. Colevas AD, Yom SS, Pfister DG, Spencer S, Adelstein D, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ et al (2018) NCCN guidelines insights: head and neck cancers, version 1.2018. J Natl Compr Canc Netw 16(5):479–490. https://doi.org/10.6004/jnccn.2018.0026

4. Sun X, Su S, Chen C, Han F, Zhao C, Xiao W, Deng X, Huang S, Lin C, Lu T (2014) Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities. Radiother Oncol J Eur Soc Therap Radiol Oncol 110(3):398–403. https://doi.org/10.1016/j.radonc.2013.10.020

5. Cao C-n, Luo J-w, Gao L, Yi J-l, Huang X-d, Wang K, Zhang S-p, Qu Y, Li S-y, Xiao J-p et al (2015) Update report of T4 classification nasopharyngeal carcinoma after intensity-modulated radiotherapy: an analysis of survival and treatment toxicities. Oral Oncol 51(2):190–194. https://doi.org/10.1016/j.oraloncology.2014.11.009